INTRODUCTION: Intentional release of Yersinia pestis will likely be propagated by aerosol exposure. We explored the effects of neutropenia on the outcome of doxycycline and gentamicin therapy. METHODS: Female BALB/c mice were exposed to 20 LD(50) of Y. pestis CO92 by aerosol. Treatments were saline (negative control), levofloxacin at 15 mg/kg every 12 h (positive control), doxycycline at 40 mg/kg every 6 h, and gentamicin at 12 mg/kg every 6 h, 24 mg/kg every 12 h, and 48 mg/kg every 24 h in cohorts of normal and neutropenic mice for 5 days. RESULTS: Control mice died. Positive control mice (levofloxacin) had 100% survivorship in both neutropenic and nonneutropenic groups. Doxycycline treatment in the presence of granulocytes yielded 90% survivorship; all neutropenic mice died after the termination of treatment (P<<.001). For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice. No significant differences were seen in the neutropenia versus normal mouse comparison or by schedule. CONCLUSIONS: Doxycycline behaves in vivo as a bacteriostatic drug, requiring an intact immune system for clearance of the infection after aerosol challenge with Y. pestis. Gentamicin is bactericidal, even when given on a daily schedule. Neutropenia did not significantly affect survivorship.
INTRODUCTION: Intentional release of Yersinia pestis will likely be propagated by aerosol exposure. We explored the effects of neutropenia on the outcome of doxycycline and gentamicin therapy. METHODS: Female BALB/c mice were exposed to 20 LD(50) of Y. pestis CO92 by aerosol. Treatments were saline (negative control), levofloxacin at 15 mg/kg every 12 h (positive control), doxycycline at 40 mg/kg every 6 h, and gentamicin at 12 mg/kg every 6 h, 24 mg/kg every 12 h, and 48 mg/kg every 24 h in cohorts of normal and neutropenicmice for 5 days. RESULTS: Control mice died. Positive control mice (levofloxacin) had 100% survivorship in both neutropenic and nonneutropenic groups. Doxycycline treatment in the presence of granulocytes yielded 90% survivorship; all neutropenicmice died after the termination of treatment (P<<.001). For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenicmice. No significant differences were seen in the neutropenia versus normal mouse comparison or by schedule. CONCLUSIONS:Doxycycline behaves in vivo as a bacteriostatic drug, requiring an intact immune system for clearance of the infection after aerosol challenge with Y. pestis. Gentamicin is bactericidal, even when given on a daily schedule. Neutropenia did not significantly affect survivorship.
Authors: Henry S Heine; Arnold Louie; Jeffrey J Adamovicz; Kei Amemiya; Randy L Fast; Lynda Miller; Steven M Opal; John Palardy; Nicolas A Parejo; Fritz Sörgel; Martina Kinzig-Schippers; George L Drusano Journal: Antimicrob Agents Chemother Date: 2014-03-31 Impact factor: 5.191
Authors: G L Drusano; O O Okusanya; A O Okusanya; B van Scoy; D L Brown; C Fregeau; R Kulawy; M Kinzig; F Sörgel; H S Heine; A Louie Journal: Antimicrob Agents Chemother Date: 2009-08-17 Impact factor: 5.191
Authors: Arnold Louie; Brian Vanscoy; Weiguo Liu; Robert Kulawy; David Brown; Henry S Heine; George L Drusano Journal: Antimicrob Agents Chemother Date: 2011-04-12 Impact factor: 5.191
Authors: Trudy H Grossman; Michael S Anderson; Lindsay Drabek; Melanie Gooldy; Henry S Heine; Lisa N Henning; Winston Lin; Joseph V Newman; Rene Nevarez; Kaylyn Siefkas-Patterson; Anne K Radcliff; Joyce A Sutcliffe Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: Jason A Rosenzweig; Sheri M Brackman; Michelle L Kirtley; Jian Sha; Tatiana E Erova; Linsey A Yeager; Johnny W Peterson; Ze-Qi Xu; Ashok K Chopra Journal: Antimicrob Agents Chemother Date: 2011-08-22 Impact factor: 5.191
Authors: Trudy H Grossman; Michael S Anderson; David Christ; Melanie Gooldy; Lisa N Henning; Henry S Heine; M Victoria Kindt; Winston Lin; Kaylyn Siefkas-Patterson; Anne K Radcliff; Vincent H Tam; Joyce A Sutcliffe Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Henry S Heine; Lara Chuvala; Renaldo Riggins; Gregory Hurteau; Ryan Cirz; Robert Cass; Arnold Louie; G L Drusano Journal: Antimicrob Agents Chemother Date: 2013-02-12 Impact factor: 5.191
Authors: Philip A Arlen; Michael Singleton; Jeffrey J Adamovicz; Yi Ding; Abdolreza Davoodi-Semiromi; Henry Daniell Journal: Infect Immun Date: 2008-05-27 Impact factor: 3.441